Targeting RNA: A Transformative Therapeutic Strategy.

Area of Science:

• Molecular Biology
• Drug Development
• Genetics

Background:

• Current therapeutic strategies focus on gene knockdown and splicing modulation.
• Oligonucleotide therapeutics represent a validated drug class targeting over 10,000 previously undruggable genetic targets.
• Recent approvals have generated excitement, but challenges remain for full potential realization.

Purpose of the Study:

• To review translational strategies for oligonucleotide therapeutics.
• Focus on preclinical evaluation and clinical development of approved oligonucleotide drugs.
• Examine drug-specific approaches in pharmacology, pharmacokinetics, cardiac safety, and dose selection.

Main Methods:

• Review of approved oligonucleotide therapeutics.
• Analysis of preclinical and clinical development strategies.
• Discussion of translational approaches including pharmacology, pharmacokinetics, cardiac safety, and dose selection.

Main Results:

• Oligonucleotide therapeutics can modulate numerous genetic targets previously inaccessible to other drug classes.
• Five oligonucleotide drugs have been approved recently, demonstrating therapeutic viability.
• Specific translational strategies are crucial for successful drug development in this class.

Conclusions:

• Oligonucleotide therapeutics are an established drug class with significant potential.
• Further innovation is needed to overcome existing challenges in the field.
• Translational strategies are key to realizing the full therapeutic promise of oligonucleotide drugs.